EGFR and triple-negative breast carcinoma: LIPTACs exhibited efficient EGFR degradation on triple-negative breast cancer cell line HCC1143 (Extended Data Fig.4c), the pancreatic cancer cell line PANC-1 (Extended Data Fig.4d), as well as the non-small cell lung cancer cell line NCI-H1975 (Extended Data Fig.4e).